Top

Published in:

Open Access 01-12-2024 | Breast Cancer | Research

The prevalence of ADSL (rs3788579) and CYP1A2 (rs17861162) polymorphisms in female breast cancer patients in North-West Iran

Authors: Mohammad Valizadeh Osalo, Parisa Hosseini, Hamed Charkhian, Hossien Soltanzadeh, Selda Goharkhany, SEREF BUGRA TUNCER

Published in: Discover Oncology | Issue 1/2024

Abstract

Introduction

Breast cancer is a prevalent and significant contributor to cancer-related mortality among women worldwide. Its increasing incidence, especially in regions like North-West Iran, necessitates a deeper understanding of genetic factors contributing to its development. Genetic alterations, particularly single nucleotide polymorphisms (SNPs), are implicated in breast cancer susceptibility, making investigation in this context crucial. This study explores the role of CYP1A2-rs17861162 and ADSL-rs3788579 SNPs in breast cancer risk among Iranian women.

Methods

This study involved 200 female breast cancer patients and 200 healthy controls in North-West Iran. DNA was extracted from blood samples, and PCR–RFLP was used for genotyping the CYP1A2 and ADSL genes.

Results

The CYP1A2-rs17861162 SNP exhibited a shift from the C allele to the G allele in breast cancer patients, resulting in a 21.7% decrease in CC genotype frequency and a 21.6% and 77.8% increase in CG and GG genotypes, respectively, compared to controls. In ADSL-rs3788579 SNP, breast cancer patients had a significantly higher prevalence of the T allele, with a 28.5% increase compared to controls. In healthy participants, CC was most common, while in the breast cancer group, TT was most common.

Conclusion

This study highlights significant genetic alterations in CYP1A2-rs17861162 and ADSL-rs3788579 SNPs among breast cancer patients in North-West Iran, suggesting their potential as diagnostic and prognostic biomarkers. Further research is warranted to elucidate the precise mechanisms underlying their contributions to breast cancer susceptibility in this population.

Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.CrossRefPubMed

Jassim GA, Doherty S, Whitford DL, Khashan AS. Psychological interventions for women with non-metastatic breast cancer. Cochrane Database Syst Rev. 2023. https://doi.org/10.1002/14651858.CD008729.pub3.CrossRefPubMedPubMedCentral

Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023. https://doi.org/10.1016/j.cell.2023.01.040.CrossRefPubMedPubMedCentral

Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Physician. 2021;104(2):171–8.PubMed

Britt KL, Cuzick J, Phillips K-A. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20(8):417–36.CrossRefPubMed

Giaquinto AN, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41.CrossRefPubMed

Fouladi N, Pourfarzi F, Amani F, Ali-Mohammadi H, Lotfi I, Mazaheri E. Breast cancer in Ardabil province in the north-west of Iran: an epidemiological study. Asian Pac J Cancer Prev. 2012;13(4):1543–5.CrossRefPubMed

Rezagholi T, et al. Estimating the burden of breast cancer in Iranian women in 2009. Iran J Epidemiol. 2015;10(4):32–40.

Aghoosi H, Majid S, Nabatchian F, Mordadi A, Khodaverdi F. Evaluation of effects of alfalfa extract and risk of breast cancer. J Payavard Salamat. 2015;8(5):415–26.

10.

Bai X, Xie J, Sun S, Zhang X, Jiang Y, Pang D. The associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern China. Oncotarget. 2017;8(24):38367.CrossRefPubMedPubMedCentral

11.

Deng C-X. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet. 2003;12(90001):113R – 123. https://doi.org/10.1093/hmg/ddg082.CrossRef

12.

Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318–24. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11%3c2318::AID-CNCR21%3e3.0.CO;2-Z.CrossRefPubMed

13.

Sheweita S, Tilmisany A. Cancer and phase II drug-metabolizing enzymes. Curr Drug Metab. 2003. https://doi.org/10.2174/1389200033336919.CrossRefPubMed

14.

Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481–4. https://doi.org/10.1158/0008-5472.CAN-05-0825.CrossRefPubMed

15.

Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect. 1997;105(suppl 4):891–6.CrossRefPubMedPubMedCentral

16.

Hashemi M, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer–pilot study of 134 cases. PLoS ONE. 2013;8(1):e53075.ADSCrossRefPubMedPubMedCentral

17.

Ioannides C. Cytochromes P450: role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: Royal Society of Chemistry; 2008.CrossRef

18.

Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2012;64(SUPPL):256–69. https://doi.org/10.1016/j.addr.2012.09.017.CrossRef

19.

Carney SA, Peterson RE, Heideman W. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin activation of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator pathway causes developmental toxicity through a CYP1A-independent mechanism in zebrafish. Mol Pharmacol. 2004;66(3):512–21.PubMed

20.

Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ. 1999;148:173–95.

21.

Bernauer U, Heinrich-Hirsch B, Tönnies M, Peter-Matthias W, Gundert-Remy U. Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol Lett. 2006;164(3):278–88. https://doi.org/10.1016/j.toxlet.2006.01.007.CrossRefPubMed

22.

Lim JSL, et al. Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet. 2010;25(6):616–23.CrossRefPubMed

23.

Perera V, Gross AS, McLachlan AJ. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin Pharmacol Ther. 2012;92(4):511–9.PubMed

24.

Dobrinas M, Cornuz J, Oneda B, Serra MK, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90(1):117–25. https://doi.org/10.1038/clpt.2011.70.CrossRefPubMed

25.

Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism–related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Prevent Biomarkers. 2005;14(8):1998–2003. https://doi.org/10.1158/1055-9965.EPI-05-0076.CrossRef

26.

Tabucchi A, Carlucci F, Rosi F, Guerranti R, Marinello E. Determination, activity and biological role of adenylosuccinate lyase in blood cells. Biomed Pharmacother. 2001;55(5):277–83. https://doi.org/10.1016/S0753-3322(01)00061-0.CrossRefPubMed

27.

Pedley AM, Benkovic SJ. A new view into the regulation of purine metabolism: the purinosome. Trends Biochem Sci. 2017;42(2):141–54. https://doi.org/10.1016/j.tibs.2016.09.009.CrossRefPubMed

28.

Zhu R, et al. ADSL, AMPD1, and ATIC expression levels in muscle and their correlations with muscle inosine monophosphate content in dapulian and hybridized pig species. Open J Anim Sci. 2017;7(04):393.CrossRef

29.

Du Wenxing XSYD. Current research advances in IMP and related enzymes. Biotechnol Bull. 2011;3:44.

30.

Yuan T, Gu J-R, Gu W-B, Wu J, Ge S-R, Xu H. Molecular cloning, characterization and expression analysis of adenylosuccinate lyase gene in grass carp (Ctenopharyngodon idella). Mol Biol Rep. 2011;38(3):2059–65. https://doi.org/10.1007/s11033-010-0331-8.CrossRefPubMed

31.

Natsumeda Y, et al. Purine enzymology of human colon carcinomas. Cancer Res. 1985;45(6):2556–9.PubMed

32.

Reed VL, Mack DO, Smith LD. Adenylosuccinate lyase as an indicator of breast and prostate malignancies: a preliminary report. Clin Biochem. 1987;20(5):349–51. https://doi.org/10.1016/S0009-9120(87)80085-1.CrossRefPubMed

33.

Jurecka A, Zikanova M, Kmoch S, Tylki-Szymańska A. Adenylosuccinate lyase deficiency. J Inherit Metab Dis. 2015;38(2):231–42.CrossRefPubMed

34.

Zurlo G, et al. Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. Nat Commun. 2019;10(1):5177.ADSCrossRefPubMedPubMedCentral

35.

McDonald ER, et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell. 2017;170(3):577–92.CrossRefPubMed

36.

Dilhari A, et al. Evaluation of the impact of six different DNA extraction methods for the representation of the microbial community associated with human chronic wound infections using a gel-based DNA profiling method. AMB Express. 2017;7:1–11.CrossRef

37.

Taghavi A, et al. Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev. 2012;13(1):367–70.CrossRefPubMed

38.

Mousavi SM, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383–91.CrossRefPubMed

39.

Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1–2):83–448.CrossRefPubMed

40.

Fuhrman BJ, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012;104(4):326–39.CrossRefPubMedPubMedCentral

41.

Bågeman E, Ingvar C, Rose C, Jernström H. Coffee consumption and CYP1A2* 1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomark Prev. 2008;17(4):895–901.CrossRef

42.

Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34(4):378–90. https://doi.org/10.1016/j.ctrv.2008.01.007.CrossRefPubMed

43.

Shan J, et al. Genetic polymorphism of estrogen metabolizing enzymes in Siberian women with breast cancer. Genet Test Mol Biomarkers. 2012;16(3):167–73. https://doi.org/10.1007/s10549-012-2202-6.CrossRef

44.

Liu J, Xi H, Jiang Y, Feng Z, Hou L, Li W. Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy. Acta Anaesthesiol Scand. 2015;59(5):640–7.CrossRefPubMed

45.

Ghotbi R, Christensen M, Roh H-K, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007;63(6):537–46. https://doi.org/10.1007/s00228-007-0288-2.CrossRefPubMed

46.

Zhou S, Wang B, Yang L, Liu J-P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010;42(2):268–354. https://doi.org/10.3109/03602530903286476.CrossRefPubMed

47.

Bageman E, Ingvar C, Rose C, Jernstrom H. Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomark Prev. 2008;17(4):895–901. https://doi.org/10.1158/1055-9965.EPI-07-0555.CrossRef

48.

Long J-R, et al. Population-based case??? control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics. 2006;16(4):237–43. https://doi.org/10.1097/01.fpc.0000189803.34339.ed.CrossRefPubMed

49.

Božina N, Bradamante V, Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arch Ind Hyg Toxicol. 2009;60(2):217–42. https://doi.org/10.2478/10004-1254-60-2009-1885.CrossRef

50.

Xiao-Feng H, et al. Association between CYP1A2 and CYP1B1 polymorphisms and colorectal cancer risk: a meta-analysis. PLoS One. 2014;9(8):e100487.CrossRef

51.

Kotsopoulos J, et al. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Prevent Biomarkers. 2007;16(5):912–6. https://doi.org/10.1158/1055-9965.EPI-06-1074.CrossRef

52.

Hong C-C, Tang B-K, Hammond GL, Tritchler D, Yaffe M, Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352. https://doi.org/10.1186/bcr798).CrossRefPubMedPubMedCentral

53.

Yan J, et al. Effects of exogenous inosine monophosphate on growth performance, flavor compounds, enzyme activity, and gene expression of muscle tissues in chicken. Poult Sci. 2018;97(4):1229–37.CrossRefPubMed

54.

Camici M, et al. Inborn errors of purine salvage and catabolism. Metabolites. 2023;13(7):787.CrossRefPubMedPubMedCentral

55.

Lim D, et al. Analysis of extended haplotype in Korean cattle (Hanwoo) population. BMB Rep. 2016;49(9):514.CrossRefPubMedPubMedCentral

56.

Gong LL. Genetic variation and expression of ADSL and GARS-AIRS-GART genes and their associations with meat quality in chicken. Yangzhou: Yangzhou University; 2011.

57.

Ye MH, Chen JL, Zhao GP, Zheng MQ, Wen J. Correlation between polymorphisms in ADSL and GARS-AIRS-GART genes with inosine 5′-monophosphate (IMP) contents in Beijing-you chickens. Br Poult Sci. 2010;51(5):609–13.CrossRefPubMed

58.

Chen S-H, et al. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia. 2011;25(1):66–74.CrossRefPubMed

59.

Park H, et al. Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate. Lab Invest. 2018;98(4):449–61.CrossRefPubMed

60.

Jiang T, et al. Targeting de novo purine synthesis pathway via ADSL depletion impairs liver cancer growth by perturbing mitochondrial function. Hepatology. 2021;74(1):233.CrossRefPubMed

61.

Melville S, Heycock L. Breast cancer: an overview. Pharm J. 2007;279:299.

62.

Álvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010;12(2):S1. https://doi.org/10.1186/bcr2730.CrossRefPubMedPubMedCentral

63.

Beck T, Hastings RK, Gollapudi S, Free RC, Brookes AJ. GWAS Central: a comprehensive resource for the comparison and interrogation of genome-wide association studies. Eur J Hum Genet. 2014;22(7):949. https://doi.org/10.1038/ejhg.2013.274.CrossRefPubMed

64.

Shan J, et al. Genome-wide association studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Breast Cancer Res Treat. 2012;135(3):715–24. https://doi.org/10.1007/s10549-012-2202-6.CrossRefPubMedPubMedCentral

Title: The prevalence of ADSL (rs3788579) and CYP1A2 (rs17861162) polymorphisms in female breast cancer patients in North-West Iran
Authors: Mohammad Valizadeh Osalo
Parisa Hosseini
Hamed Charkhian
Hossien Soltanzadeh
Selda Goharkhany
SEREF BUGRA TUNCER
Publication date: 01-12-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00919-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

The application of plant-exosome-like nanovesicles as improved drug delivery systems for cancer vaccines

Identifying the tumor immune microenvironment-associated prognostic genes for prostate cancer

The predictive value of NLR, PLR and MLR in the differential diagnosis of benign uterine diseases and endometrial malignant tumors

Should we consider Systemic Inflammatory Response Index (SIRI) as a new diagnostic marker for rectal cancer?

Elevated histone deacetylase 10 expression promotes the progression of clear cell renal cell carcinoma by Notch-1-PTEN signaling axis

Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials